"Phosphorus" in the heat of the summer

01

Title: Protein tyrosine phosphatase PTPN22 negatively modulates platelet function and thrombus formation

Application area: Cardiovascular disease

Impact factor: 25.

Published Journal: Blood

Omics Technology: TMT Phosphorylome

Introduction: Protein tyrosine phosphatase non-receptor 22 (PTPN22) is a protein tyrosine phosphatase that negatively regulates T cell signaling

Phenotypic findings - PTPN22 is expressed in platelets and PTPN22 deficiency leads to hemostasis and arterial thrombosis in vivo

Mechanistic studies [apparent level] (immunoassay, microscopic assessment) - PTPN22-deficient platelets have enhanced aggregation, enhanced granule secretion, enhanced αIIbβ3 activation and calcium mobilization, platelet lamina formation, spreading, and clot shrinkage

Mechanistic studies [molecular level] (TMT phosphorylome, etc.

Title: Breviscapine alleviates NASH by inhibiting TGF-β-activated kinase 1-dependent signaling

Application field: pharmacological drug target

Impact factor: 17.

Published journal: Hepatology

Omics technology: transcriptome + proteome + phosphorylation

Introduction: Breviscapine is a natural flavonoid prescription drug isolated from breviscapine, which has a wide range of pharmacological effects, including effects on metabolism

Phenotypic findings - Breviscapine can alleviate high-fat diet-induced liver injury and metabolic disorders in mice; can alleviate steatohepatitis induced by HFHC and MCD diets; can reduce hepatocyte lipid accumulation and inflammatory response

Mechanism studies (transcriptomic, proteomic, phosphoromic assays) - Breviscapine prevents NASH by systematically blunting the pathways of lipid metabolism, inflammation, fibrosis and apoptosis; Breviscapine inhibits the liver under metabolic stress Mitogen-activated protein kinase pathway in cells and liver tissue; breviscapine inhibits lipid accumulation and hepatocyte pro-inflammatory responses by inhibiting TAK1

Title: Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis

Application field: pharmacological drug target

Impact factor: 31.

Published Journal: Cell Metabolism

Omics technology: label-free phosphorylation + DIA

Introduction: Non-alcoholic steatohepatitis (NASH) is an extreme form of non-alcoholic fatty liver disease, but there is no specific treatment

Phenotypic findings - low-dose sorafenib improves NASH

Mechanistic studies (phosphoryome) - NASH mass improvement by enhancing mitochondrial proton leak-activated AMPK signaling by inducing mitochondrial uncoupling
.

Clinical efficacy assessment (DIA proteome, transcriptome analysis, etc.
) - Sorafenib improves steatosis, inflammation, fibrosis, etc.
in a non-human primate cynomolgus monkey model
.

The content of this issue is over here.
I believe that the teacher has some understanding of the application of phosphorylation in the medical mouth.
Let's meet again in the next issue of "The application of phosphorylation in the agricultural mouth"
.
Recently, the new life summer phosphorylation promotion of Zhongke New Life is going on, and interested teachers are welcome to come and consult
.